

PUBLICATIONS 2011

Peer Reviewed

Bassam Abdulkarim, Julie Cuartero, John Hanson, Jean Deschenes, David Lesniak and **Siham Sabri**. Increased Risk of Locoregional Recurrence for Women with T1-2N0 Triple Negative Breast Cancer Treated with Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy. *Journal of Clinical Oncology*, 2011 Jul 20; 29(21): 2852-8.

Mackay H, Au H, McWhirter E, **Alcindor T**, Jarvi A, MacAlpine K, Wang L, Wright JJ, Oza AM. A phase II trial of the Src kinase inhibitor AZD0530 in patients with metastatic or locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A trial of the PMH phase II consortium. *Investigational New Drugs*. 2011 Mar 12. [Epub ahead of print]

Alcindor T, Beauger N. Oxaliplatin: A review in the era of molecularly targeted therapy. *Current Oncology*. 2011 Jan 18(1):18-25.

Ferri LE, Ades S, **Alcindor T**, Chasen M, Hickeson M, Artho G, Marcus V, **Thirlwell MP**. Peri-Operative Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) for Locally Advanced Esophageal and Gastric Adenocarcinoma: Safety and Response Results from a Multi-Center Phase II Trial. *Annals of Oncology*. Ann Oncol. 2011 Oct 29. [Epub ahead of print]

Yoon JY, Kumar R, **Aloyz R**, Johnston JB. Response of concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia to imatinib mesylate. *Leuk Res*. 2011 Sep;35(9):e179-80. Epub 2011 Jul 28. PubMed PMID: 21802141.

Martinez-Marignac VL, Rodrigue A, Davidson D, Couillard M, Al-Moustafa AE, Abramovitz M, **Foulkes WD**, Masson JY, **Aloyz R**. The effect of a DNA repair gene on cellular invasiveness: XRCC3 over-expression in breast cancer cells. *PLoS One*. 2011 Jan 24;6(1):e16394.

Mokrani N, Felfoul O, Afkhami Zarreh F, Mohammadi M, **Aloyz R**, **Batist G**, Martel S. Magnetotactic bacteria penetration into multicellular tumor spheroids for targeted therapy. *Conf Proc IEEE Eng Med Biol Soc*. 2010;2010:4371-4.

Amrein L, Soulières D, Johnston JB, **Aloyz R**. p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes. *Leuk Res*. 2011 Jan;35(1):99-102. Commented in the Editorial

Mahmud SM(*§), **Franco EL**, Turner D, Platt Rw, Beck P, Skarsgard D, Tonita J, Sharpe C, **Aprikian AG**. Use of Non-Steroidal Anti-Inflammatory Drugs and Prostate Cancer Risk: A population-based nested case-control study. *Public Library of Science – One* 6(1):e16412, 2011.

Aubin, S. (2011). What should the age range be for AYA oncology? *Journal of Adolescent and Young Adult Oncology*, 1(1), 3.

Batist G, Hui Wu J, Spatz A, Miller WH Jr, Cocolakis E, Rousseau C, Diaz Z, Ferrario C, Basik M. Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies. *Frontiers in Pharmacology of Anti-Cancer Drugs*. doi: 10.3389/fphar.2011.00059. [Epub 2011 Oct 5].

Fiset, E. Xu*, S. Bergeron, A. Marette, G. Pelletier, K.L. Siminovitch, M. Olivier, **N. Beauchemin**, and R.L. Faure. Compartmentalized Cdk2 is connected with SHP-1 and b-catenin and regulates insulin internalization. *Cell Signaling*, 23(5):911-9 (2011).

D. Gerstel, F. Wegwitz, K. Jannasch, P. Ludewig, K. Scheike, F. Alves, **N. Beauchemin**, W. Deppert, C. Wagener and A. K. Horst. CEACAM1 creates a pro-angiogenic micro-environment that supports tumor vessel maturation. *Oncogene*, 30(41):4275-88. (2011).

C. Meunier,* T. Kwan, C. Turbide*, **N. Beauchemin*** and **P. Gros***. Genetic Control of Susceptibility to Carcinogen-Induced Colorectal Cancer in Mice: The *Ccs3* and *Ccs5* Loci Regulate Different Aspects of Tumorigenesis. *Cell Cycle*, 10 (11) 1739-49 (2011). *co-senior author.

N. Beauchemin. The Colorectal Tumor Microenvironment: The Next Decade. *Cancer Microenvironment*. 4: 181-5 (2011).

S. X. Lu, L.W. Kappel, A.-M. Charbonneau-Allard, R. Atallah, A.M. Holland, C. Turbide, V. M. Hubbard, J.A. Rotolo, J.M. Smith, D. Suh, C. King, U.K. Rao, N. Yim, J.L. Bautista, R. R. Jenq, O. Penack, I.-K. Na, C. Liu, G. Murphy, S.O. Alpdogan, R.S. Blumberg, F. Macian, K.V. Holmes, **N. Beauchemin***, M. R.M. van den Brink*. *Ceacam1* separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation. *PLoS One*. 6 (7), e21611 (2011). *, co-senior author.

S. LeBlanc*, A.L. Nouvion*, A. Arabzadeh, S. Benlolo, V. Breton, C. Turbide and **N. Beauchemin**. CEACAM1 deficiency delays wound healing. *Wound Repair and Regeneration* 19(6):745-52 (2011). * contributed equally to the work..

Z. Chen, L. Chen, K. Baker, T. Olszak, S. Zeissig, O. Mandelboim, **N. Beauchemin**, L. L. Lanier and R.S. Blumberg. CEACAM1 dampens anti-tumor immunity via bidirectional down-regulation of NKG2D ligand expression on tumor cells and NKG2D function on NK cells. *J. Exp. Med.* 208(13):2633-40 (2011).

Puts MTE, **Monette J.**, Girre V., **Pepe C.**, Monette M., **Assouline S.**, **Panasci L.**, **Basik M.**, **Miller WH Jr.**, **Batist G.**, Wolfson C., **Bergman H.** Are frailty markers useful for predicting treatment toxicity and mortality in older newly-diagnosed cancer patients? Results from a prospective pilot study. *Critical Reviews in Oncology Hematology* **78(2)**:138-149, 2011.

Noah B. Sands, MD, Shawn Karls, BSc, Alexander Amir, BSc, Michael Tamilia, MD, FRCPC, Olga Gologan, MD, FRCPC, Louise Rochon, MS, FRCPC, **Martin J. Black, MD, FRCSC, Michael P. Hier, MD, FRCSC**, and Richard J. Payne, MD, MSc, FRCSC, McGill Thyroid Nodule Score (MTNS): "Rating the Risk", a Novel Predictive Scheme for Cancer Risk Determination, *Journal of Otolaryngology-Head and Neck Surgery*, Vol 40, No S1 (February), 2011;pp S1-S13

Abdul-Sater L, Henry M, Majdan A, Mijovic T, Franklin JH, Brandt MG, **Black MJ, Hier MP**, Payne RJ, What are Thyroidectomy Patients Really Concerned About? *Otolaryngology Head Neck; Surgery*, 2011 Mar 1.

Sands N, Young J, MacNamara E, **Black MJ**, Tamilia M, **Hier MP**, Payne RJ, Preoperative Parathyroid Hormone Levels as a Predictor of Postthyroidectomy Hypocalcemia; *Otolaryngology Head Neck; Surgery*, 2011 Apri;144(4):518-521.

Michael Tamilia, Nora Al-Kahtani, Louise Rochon, **Michael P. Hier**, Tichard J. Payne, Christina A. Holcroft and **Martin J. Black**, Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma. *Nuclear Medicine Communications*, Vol. 32 No. 3 March 2011

Walz J, Marcy M, Maubon T, Brunelle S, Laroche J, Gravis G, Salem N, **Bladou F**. [Real time elastography in the diagnosis of prostate cancer: comparison of preoperative imaging and histology after radical prostatectomy]. *Prog Urol*. 2011 Dec;21(13):925-31. doi: 10.1016/j.purol.2011.04.006. Epub 2011 Jun 2. French. PubMed PMID: 22118357.

Minaya P, Baumstarck K, Berbis J, Goncalves A, Barlesi F, Michel G, Salas S, Chinot O, Grob JJ, Seitz JF, **Bladou F**, Clement A, Mancini J, Simeoni MC, Auquier P. The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): Development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer. *Eur J Cancer*. 2011 Oct 25. [Epub ahead of print] PubMed PMID: 22033328.

Bastide C, Rossi D, Lechevallier E, **Bladou F**, Barriol D, Bretheau D, Grisoni V, Mancini J, Giusiano S, Eghazarian C, Van Hove A. Seminal vesicle invasion: what is the best adjuvant treatment after radical prostatectomy? *BJU Int*. 2011 Aug 18. doi: 10.1111/j.1464-410X.2011.10332.x. [Epub ahead of print] PubMed PMID: 21851534.

Beyer L, Troyer JD, Mancini J, **Bladou F**, Berdah SV, Karsenty G. Impact of laparoscopy simulator training on the technical skills of future surgeons in the operating room: a prospective study. *Am J Surg*. 2011 Sep;202(3):265-72. Epub 2011 Jun 12. PubMed PMID: 21658672.

Sabatier R, Eymard JC, Walz J, Deville JL, Narbonne H, Boher JM, Salem N, Marcy M, Brunelle S, Viens P, **Bladou F**, Gravis G. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? *Ann Oncol*. 2011 Jun 8. [Epub ahead of print] PubMed PMID: 21653681.

Walz J, Marcy M, Pianna JT, Brunelle S, Gravis G, Salem N, **Bladou F**. Identification of the prostate cancer index lesion by real-time elastography: considerations for focal therapy of prostate cancer. *World J Urol.* 2011 Oct;29(5):589-94. Epub 2011 May 26. PubMed PMID: 21614469.

Bessede T, Beuzeboc P, **Bladou F**, Fizazi K, Mongiat-Artus P, Villers A. [Strategies in castration-resistant prostate cancer]. *Prog Urol.* 2011 Mar;21 Suppl 2:S68-71. French. PubMed PMID: 21397833.

Perrin J, Saïas-Magnan J, Lanteaume A, Thiry-Escudié I, Serment G, **Bladou F**, Gamberre M, Grillo JM, Karsenty G. [Initial results of a novel technique for sperm retrieval in male infertility due to refractory retrograde ejaculation]. *Prog Urol.* 2011 Feb;21(2):134-8. Epub 2010 Oct 14. French. PubMed PMID: 21296282.

Zhang, Z., M. Z. Mui, F. Chan, D.E. Roopchand, R.C. Marcellus, P. Blanchette, S. Li, A.M. Berghuis and **P.E. Branton**. 2011. Genetic analysis of B55 α /Cdc55 PP2A subunits: Association with the adenovirus E4orf4 protein. *J. Virol.* 85, 286-295.

Cheng, C.Y., T. Gilson, F. Dallaire, G. Ketner, **P.E. Branton** and P. Blanchette. 2011. The E4orf6/E1B55K E3 ubiquitin ligase complexes of human adenoviruses exhibit heterogeneity in composition and substrate specificity. *J. Virol.* 85, 765-775.

Schreiner, S., P. Wimmer, P. Groitl, A. Chan, P. Blanchette, **P.E. Branton**, and T. Dobner. 2011. Adenovirus type 5 early region 1B 55K oncoprotein dependent degradation of cellular factor Daxx is required for efficient transformation of primary rodent cells. *J. Virol.* 85, 8752-8765.

Mehta A, **Cohen SR**, Ezer H, Carnevale F, Ducharme F. Striving to respond to palliative care patients' pain at home: a puzzle for family caregivers. *Oncol Nurs Forum.* 2011 Jan 1; 38(1): E37-45. [doi:10.1188/11.ONF.E37-E45](https://doi.org/10.1188/11.ONF.E37-E45). *Highlighted in the American Academy of Pain Management e-newsletter, Feb 2011.*

Williams AM, Eby JA, Crooks VA, Stajduhar K, Giesbrecht M, Vuksan M, **Cohen SR**, Brazil K, Allan D. Canada's Compassionate Care Benefit: Is it an adequate public health response to addressing the issue of caregiver burden in end-of-life care? *BMC Public Health.* 2011; 11(1): 335. [doi:10.1186/1471-2458-11-335](https://doi.org/10.1186/1471-2458-11-335).

Jones J, McPherson C, Zimmermann C, Rodin G, **Cohen SR**. Assessing agreement between terminally ill cancer patients' reports of their quality of life with family caregiver and palliative care physician proxy ratings. *J Pain Symptom Manage.* 2011 Sep; 42(3); 354-365. [doi:10.1016/j.jpainsymman.2010.11.018](https://doi.org/10.1016/j.jpainsymman.2010.11.018).

Stajduhar K, Funk L, **Cohen SR**, Williams A, Bidgood D, Allan D, Norgrove L, Heyland D. Bereaved family members' assessments of the quality of EOL care: What is important? *J Palliat Care* 2011; 27(4):261-269.

Kerachian MA, Harvey EJ, **Cournoyer D**, Chow TY, Nahal A, Seguin C. A Rat Model of Early Stage Osteonecrosis Induced by Glucocorticoids. *J Orthop Surg Res.* 2011 Dec 21;6(1):62.

F. Cury, M. Duclos, A. Aprikian, H. Patrocínio, W. Kassouf, G. Shenouda, S. Faria, M. David, & L. Souhami. Single-Fraction High Dose at Brachytherapy and Hypofractionated External Beam Radiation Therapy in the Treatment of Intermediate-Risk Prostate Cancer-Long term Results. McGill University Health Center, Montreal QC Accepted to be published in *Int. Journal of Radiation Oncology Biology Physics* 2011 (pp. 1-7, 2011)

S. Aldelaijan, H. Mohammed, N. Tomic, L. Liang, **F. DeBlois, A. Sarfehnia, W. Abdel-Rahman, J. Seuntjens, S. Devic**, “Radiochromic film dosimetry of HDR (192)Ir source radiation fields”, *Med. Phys.* vol. 38 (11) pp. 6074 (2011)

J. Boivin, N. Tomic, B. Fadlallah, **F. DeBlois, S. Devic** “Reference dosimetry during diagnostic CT examination using XR-QA radiochromic film model”, *Med. Phys.* vol. 38 (9) pp. 5119-29 (2011)

S. Devic, “Radiochromic film dosimetry: Past, present, and future,” *Physica Medica* **27**, 122-134 (2011).

A. Nobah, B. Mofteh, N. Tomic, **S. Devic**, “Influence of electron density spatial distribution and x-ray beam quality during CT simulation on dose calculation accuracy,” *Journal of Applied Clinical Medical Physics* **12**, 80-89 (2011).

S. Aldelaijan, H. Mohammed, N. Tomic, L. Liang, **F. DeBlois, A. Sarfehnia, W. Abdel-Rahman, J. Seuntjens, and S. Devic**, “Radiochromic film dosimetry of HDR 192Ir source radiation fields,” *Med. Phys.* **38**, 6074-6083 (2011).

Karen Lim, William Small, Jr., Lorraine Portelance, David Gaffney, Beth Erickson, Jennifer de los Santos, Satoshi Ishikura, Carien Creutzberg; Walter Bosch; **Issam El Naqa** and Anthony Fyles, “Consensus Guidelines For Delineation Of Clinical Target Volume For Intensity-Modulated Pelvic Radiotherapy For The Intact Cervix,” *Int. J. Radiation Oncology Biol. Phys.* **2011**

Ellen X. Huang, J. O. Deasy, M. Trovo, **I. El Naqa**, A.J. Hope, P. E. Lindsay, and J. D. Bradley, The Impact of Heart and Lung Irradiation on the Risk of Radiation Pneumonitis: modeling based on institutional data, *Acta Oncologica*, 50(1):51-60, 2011.

Deshan Yang, Ryan S Brame , Issam El Naqa , Aditya Apte , Yu Wu , SreeKrishna Murty Goddu , Sasa Mutic , Joseph Deasy , Daniel A Low, “DIRART - A software suite for deformable image registration and adaptive radiotherapy research”, *Medical Physics*, 2011 Jan;38(1):67-77.

Jung Hun Oh, Jeffrey Craft, Rawan Al-Lozi, Manushka Vaidya, Yifan Meng, Joseph O Deasy, Jeffrey D Bradley and **Issam El Naqa**, “A Bayesian network approach for modeling local failure in lung cancer.” *PMB*, 56 (2011) 1635–1651.

Jung Hun Oh, Jeffrey M. Craft, Reid Townsend, Joseph O. Deasy, Jeffrey D. Bradley, and **Issam El Naqa**, “A Bioinformatics Approach for Biomarker Identification in Radiation-Induced Lung Inflammation from Limited Proteomics Data,” *Journal of Proteomics Research (JPR)*, 10(3):1406-15, 2011.

Benjamin White, Daniel Low, Tianyu Zhao, Sara Wuenschel, Wei Lu, Sasa Mutic, **Issam El Naqa**, “An Investigation of a Prospective Pulmonary Gating Algorithm for 4D Computed Tomography Simulation,” *Medical Physics*, 2011 Mar;38(3):1587-95.

Stephanie M. Perkins, Joshua B. Rubin, Jeffrey R. Leonard, Matthew D. Smyth, **Issam El Naqa**, Joseph R. Simpson, Tae S. Park, David B. Mansur, *Glioblastoma in Children: A Single Institution Experience*, *IJROBP*, 2011 Jul 15;80(4):1117-21

Wang D, Bosch W, Kirsch DG, Al Lozi R, **El Naqa I**, Roberge D, Finkelstein SE, Petersen I, Haddock M, Chen YL, Saito NG, Hitchcock YJ, Wolfson AH, Delaney TF, “Variation in the Gross Tumor Volume and Clinical Target Volume for Preoperative Radiotherapy of Primary Large High-Grade Soft Tissue Sarcoma of the Extremity Among Rtog Sarcoma Radiation Oncologists,” *IJROBP*, 2011 Dec 1;81(5):e775-80

Olsen JR, Robinson CG, **El Naqa I**, Creach KM, Drzymala RE, Bloch C, Parikh PJ, Bradley JD, “Dose-Response for Stereotactic Body Radiotherapy in Early-Stage Non-Small-Cell Lung Cancer,” *Int J Radiat Oncol Biol Phys*. 2011 Apr 6. [Epub ahead of print].

Manushka Vaidya, Kimberly M. Creach, Jennifer Frye, Farrokh Dehdashti, Jeffrey D. Bradley, and **Issam El Naqa**, “Using FDG-PET/CT Image Characteristics for Predicting Radiotherapy Response in Lung Cancer,” *Radiotherapy and Oncology*, 2011 Nov 16

S. Faria, AD. Pra, **F. Cury**, **M. David**, **M. Duclos**, **CR. Freeman**, & **L. Souhami**. Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone. McGill University Health Center, Montreal QC. *Radiother. Oncol.* 2011; 101(3):486-9

Fitzpatrick, T. R. & Remmer, J. (2011). Needs, Expectations and Attendance among Users of a Cancer Wellness Centre. *Journal of Cancer Survivorship*, 5, 235-246.

Fitzpatrick, T. R. & **Farone, D. W.** (2011). Leisure, Household Activities and Health among Mexican American Elders with Cancer. *Journal of Psychosocial Oncology*, 29, 199-214.

Rio Frio T, Bahubeshi MA, Kanellopoulou C, Hamel N, Niedziela M, Sabbaghian N, Pouchet C, Gilbert L, O'Brien PK, Serfas K, Broderick P, Houlston R, Lesueur F, Bonora E, Muljo S, Schimke N, Bouron-Dal Soglio D, Arseneau J, Schultz KA, Priest J, Nguyen V, Harach R, Livinston D, **Foulkes WD**, **Tischkowitz M**. *DICER1* Mutations in multinodular goiter with and without Ovarian Sertoli-Leydig Tumors. *JAMA* 2011 Jan 305 (1), 68-77. *NB WDF is corresponding author*

Hamel N, Feng BJ, Foretova L, Stoppa-Lyonnet D, Narod SA, Imyanitov E, Sinilnikova O, Tihomirova L, Lubinski J, Gronwald J, Gorski B, Hansen TV, Nielsen FC, Thomassen M,

Yannoukakos D, Konstantopoulou I, Zajac V, Ciernikova S, Couch FJ, **Greenwood CM**, Goldgar DE, **Foulkes WD**. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. *Eur J Hum Genet*. 2011 Mar;19(3):300-6.

Shuen AY, **Foulkes WD**. Inherited mutations in breast cancer genes--risk and response. *J Mammary Gland Biol Neoplasia*. 2011 Apr;16(1):3-15. Review.

Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, **Foulkes WD**, Rosen B, Sun P, Narod SA. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. *Br J Cancer*. 2011 Apr 26;104(9):1384-92.

Metcalfe K, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, Eisen A, **Foulkes WD**, Rosen B, Vesprini D, Sun P, Narod SA. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat*. 2011 May;127(1):287-96.

Bernatsky S, Ramsey-Goldman R, **Foulkes WD**, Gordon C, Clarke AE. Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. *Br J Cancer*. 2011 Apr 16;104(9):1478-81. Epub 2011 Apr 12.

Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, **Foulkes WD**, Ghadirian P, Lynch H, Couch F, Wong J, Wright F, Sun P, Narod SA. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. *J Clin Oncol*. 2011 May 1;29(13):1664-9.

Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, **Foulkes WD**, Neuhausen S, Ainsworth P, Pollak M, Sun P, Narod SA; the Hereditary Breast Cancer Clinical Study Group. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. *Cancer*. 2011 May 1;117(9):1812-8.doi: 10.1002/ncr.25595

Ha KCh, Lalonde E, Li L, Cavallone L, Natrajan R, Lambros MB, Mitsopoulos C, Hakas J, Kozarewa I, Fenwick K, Lord CJ, Ashworth A, Vincent-Salomon A, Basik M, Reis-Filho JS, Majewski J, **Foulkes WD**. Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines. *BMC Med Genomics*. 2011 Oct 27;4:75.

Peixoto A, Santos C, Pinheiro M, Pinto P, Soares MJ, Rocha P, Gusmão L, Amorim A, van der Hout A, Gerdes AM, Thomassen M, Kruse TA, Cruger D, Sunde L, Bignon YJ, Uhrhammer N, Cornil L, Rouleau E, Lidereau R, Yannoukakos D, Pertesi M, Narod S, Royer R, Costa MM, Lazaro C, Feliubadaló L, Graña B, Blanco I, de la Hoya M, Caldés T, Maillet P, Benais-Pont G, Pardo B, Laitman Y, Friedman E, Velasco EA, Durán M, Miramar MD, Valle AR, Calvo MT, Vega A, Blanco A, Diez O, Gutiérrez-Enríquez S, Balmaña J, Ramon Y Cajal T, Alonso C, Baiget M, **Foulkes WD**, **Tischkowitz M**, Kyle R, Sabbaghian N, Ashton-Prolla P, Ewald IP, Rajkumar T, Mota-Vieira L, Giannini G, Gulino A, Achatz MI, Carraro DM, de Paillerets BB, Remenieras A, Benson C, Casadei S, King MC, Teugels E, Teixeira MR. International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. *Breast Cancer Res Treat*. 2011 Jun;127(3):671-9.

Bahubeshi A, Tischkowitz M, **Foulkes WD**. miRNA Processing and Human Cancer: DICER1 Cuts the Mustard. *Sci Transl Med*. 2011 Nov 30;3(111):111ps46.

Vijai J, Kirchhoff T, Gallagher D, Hamel N, Guha S, Darvasi A, Lencz T, **Foulkes WD**, Offit K, Klein R. Prostate cancer risk SNPs in the Ashkenazi. *Br J Cancer*. 2011 Aug 9. doi: 10.1038/bjc.2011.307.

Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, **Foulkes WD**. Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. *Histopathology*. 2011 Jun;58(7):1107-16. doi: 10.1111/j.1365-2559.2011.03846.x.

Raskin L, Schwenter F, Freytsis M, **Tischkowitz M**, Wong N, Chong G, Narod S, Levine D, Bogomolny F, Aronson M, Thibodeau S, Hunt K, Rennert G, Gallinger S, Gruber S, **Foulkes WD**. Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome. *Clin Genet*. 2011 Jun;79(6):512-522

Lu L, Cancel-Tassin G, Valeri A, Cussenot O, Lange EM, Cooney KA, Farnham JM, Camp NJ, Cannon-Albright LA, Tammela TL, Schleutker J, Hoegel J, Herkommer K, Maier C, Vogel W, Wiklund F, Emanuelsson M, Grönberg H, Wiley KE, Isaacs SD, Walsh PC, Helfand BT, Kan D, Catalona WJ, Stanford JL, Fitzgerald LM, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Thibodeau SN, McDonnell SK, Hebring S, Schaid DJ, Whittemore AS, Oakley-Girvan I, Hsieh CL, Powell I, Bailey-Wilson JE, Cropp CD, Simpson C, Carpten JD, Seminara D, Zheng SL, Xu J, Giles GG, Severi G, Hopper JL, English DR, **Foulkes WD**, Maehle L, Moller P, Badzioch MD, Edwards S, Guy M, Eeles R, Easton D, Isaacs WB; International Consortium for Prostate Cancer Genetics. Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. *Prostate*. 2011 Jul 11. doi: 10.1002/pros.21443. [Epub ahead of print]

Allen C, **Foulkes WD**. Qualitative thematic analysis of consent forms used in cancer genome sequencing. *BMC Med Ethics*. 2011 Jul 19;12(1):14.

Jarry J, Brunet JS, Laframboise R, Drouin R, Latreille J, Richard C, Gekas J, Maranda B, Monczak Y, Wong N, Pouchet C, Zaor S, Kasprzak L, Palma L, Wu MK, **Tischkowitz M, Foulkes WD**, A survey of APC mutations in Quebec. Chong G. *Fam Cancer*. 2011 Dec;10(4):659-65.

Lubinski J, Huzarski T, Byrski T, Lynch HT, Cybulski C, Ghadirian P, Stawicka M, **Foulkes WD**, Kilar E, Kim-Sing C, Neuhausen SL, Armel S, Gilchrist D, Sweet K, Gronwald J, Eisen A, Gorski B, Sun P, Narod SA; The Hereditary Breast Cancer Clinical Study Group. The risk of breast cancer in women with a BRCA1 mutation from north america and poland. *Int J Cancer*. 2011 Aug 10. doi: 10.1002/ijc.26369. [Epub ahead of print]

Appleby-Tagoe JH, **Foulkes WD**, Palma L. Reading Between the Lines: A Comparison of Responders and Non-responders to a Family History Questionnaire and Implications for Cancer Genetic Counselling. *J Genet Couns*. 2011 Aug 16. [Epub ahead of print]

Lachapelle J, **Foulkes WD**. Triple-negative and basal-like breast cancer: implications for oncologists. *Curr Oncol*. 2011 Aug;18(4):161-4.

Nalwoga H, Arnes JB, Stefansson IM, Wabinga H, **Foulkes WD**, Akslen LA. Vascular proliferation is increased in basal-like breast cancer. *Breast Cancer Res Treat*. 2011 Aug 28. [Epub ahead of print]

Arnes JB, Stefansson IM, Straume O, Baak JP, Lønning PE, **Foulkes WD**, Akslen LA. Vascular proliferation is a prognostic factor in breast cancer. *Breast Cancer Res Treat*. 2011 Sep 27. [Epub ahead of print]

Cote S, Arcand SL, Royer R, Nolet S, Mes-Masson AM, Ghadirian P, **Foulkes WD**, **Tischkowitz M**, Narod SA, Provencher D, **Tonin PN**. The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent. *Breast Cancer Res Treat*.131(1):333-40. Epub 2011 Sep 27.

Osher DJ, Kushner YB, Arseneau J, **Foulkes WD**. Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks? *J Clin Pathol*. 2011 Oct;64(10):924-6.

Foulkes WD, Bahubeshi A, Hamel N, Pasini B, Asioli S, Baynam G, Choong CS, Charles A, Frieder RP, Dishop MK, Graf N, Ekim M, Bouron-Dal Soglio D, Arseneau J, Young RH, Sabbaghian N, Srivastava A, **Tischkowitz MD**, Priest JR. Extending the Phenotypes Associated with DICER1 Mutations. *Hum Mutat*. 2011 Dec;32(12):1381-4.

Heravi-Moussavi A, Anglesio MS, Cheng S-WG, Senz J, Yang W, Prentice L, Fejes AP, Chow C, Tone A, Kalloger SE, Hamel N, Roth A, Ha G, Wan ANC, Maines-Bandiera S, Salamanca C, Pasini B, Clarke BA, Lee AF, Lee C-H, Zhao C, Young RH, Aparicio SA, Sorensen PHB, Woo MMM, Boyd N, Jones SJM, Hirst M, Marra MA, Gilks B, Shah SP, **Foulkes WD**, Morin GB, Huntsman DG. Recurrent somatic DICER1 mutations in non-epithelial ovarian cancers. *N Engl J Med* 2011, Dec 21. [Epub ahead of print]

Jin G, Lu L, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Cannon-Albright LA, Camp NJ, Teerlink CC, Fitzgerald LM, Stanford JL, Wiley KE, Isaacs SD, Walsh PC, **Foulkes WD**, Giles GG, Hopper JL, Severi G, Eeles R, Easton D, Kote-Jarai Z, Guy M, Rinckleb A, Maier C, Vogel W, Cancel-Tassin G, Egrot C, Cussenot O, Thibodeau SN, McDonnell SK, Schaid DJ, Wiklund F, Grönberg H, Emanuelsson M, Whittemore AS, Oakley-Girvan I, Hsieh CL, Wahlfors T, Tammela T, Schleutker J, Catalona WJ, Zheng SL, Ostrander EA, Isaacs WB, Xu J; International Consortium for Prostate Cancer Genetics. Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). *Hum Genet*. 2011 Dec 25. [Epub ahead of print]

Dufresne S, Sauthier P, Mayrand Mh, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis Mj, Michon B, Ouellet S, Hadjeres R, Ferenczy A, **Franco EL**, Coullée F(*). Human Papillomavirus (HPV) DNA triage of women with Atypical Squamous Cells of Undetermined Significance (ASCUS) with AMPLICOR HPV and Hybrid Capture 2 Assays for the Detection of High-grade Lesions of the Uterine Cervix. *Journal of Clinical Microbiology* 49: 48-53, 2011.

Cerigo H, **Macdonald ME**, **Franco EL**, Brassard P(*). Awareness and knowledge about human papillomavirus among Inuit women in Nunavik, Quebec. *Journal of Community Health* 36: 56-62, 2011.

Tomita LY(§), Roteli-Martins CM, Villa LL, **Franco EL**, Cardoso MA(*), For the BRINCA Study Team. Associations of dietary dark green and deep yellow vegetables and fruits with cervical intraepithelial neoplasia: modification by smoking. *British Journal of Nutrition* 105: 928-937, 2011.

Ferguson R(§), Ramanakumar AV, Richardson H, Tellier PP, Coutlée F, **Franco EL**, Roger M(*). Human leukocyte antigen (HLA)-E and HLA-G polymorphisms in human papillomavirus infection susceptibility and persistence. *Human Immunology* 72(4):337-341, 2011.

De Pokomandy A(§), Rouleau D, Ghattas G, Trottier H, Vézina S, Coté P, Macleod J, Allaire G, Hadjeres R, **Franco EL**, Coutlée F(*). HAART and Progression to High-Grade Anal Intraepithelial Neoplasia in Men Who Have Sex with Men and Are Infected with HIV. *Clinical Infectious Diseases* 52:1174-1181, 2011.

Sénécal M(*), Brisson M, Maunsell E, Ferenczy A, **Franco EL**, Ratnam S, Coutlée F, Palefsky JM, Mansi JA. Loss of quality of life associated with genital warts: baseline analyses from a prospective study. *Sexually Transmitted Infection* 87:209-215, 2011.

Coutlée F(*), Ratnam S, Ramanakumar Av, Insinga Rr, Bentley J, Escott N, Ghatage P, Koushik A, Ferenczy A, **Franco EL**. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. *Journal of Medical Virology* 83:1034-1041, 2011.

Brisson M(*), Van De Velde N, **Franco EL**, Drolet M, Boily MC. Incremental impact of adding boys to current HPV vaccination programmes: role of herd immunity. *Journal of Infectious Diseases* 204(3): 372-376, 2011.

Vanni T(§*), Legood R, **Franco EL**, Villa LL, Luz Pm, Schwartzmann G. Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. *International Journal of Cancer* 129(3): 671-679, 2011.

Sangwa-Lugoma G(§), Ramanakumar AV, Mahmud S, Liaras J, Kayembe PK, Tozin RR, Lorincz A, **Franco EL**(*). Prevalence and determinants of high-risk human papillomavirus infection in women from a sub-Saharan African community. *Sexually Transmitted Diseases* 38(4): 308-315, 2011.

Drolet M, Brisson M(*), Maunsell E, **Franco EL**, Coutlée F, Ferenczy A, Ratnam S, Fisher W, Mansi J. The impact of anogenital warts on health-related quality of life: a 6-month prospective study. *Sexually Transmitted Diseases* 38: 949-956, 2011.

Tota JE(§), Chevarie-Davis M, Richardson La, Devries M, **Franco EL**(*). Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. *Preventive Medicine* 53 (Suppl 1): S12-21, 2011.

Burchell AN(§*), Coullée F, Tellier PP, Hanley J, **Franco EL**. Genital transmission of human papillomavirus in recently-formed, heterosexual couples. *Journal of Infectious Diseases* 204(11):1723-1729, 2011.

Legault V, Burchell A, Goggin P, Nicolau B, Forest P, Mayrand Mh, **Franco EL**, Coullée F(*). Generic Microtiter Plate Assay for Triaging Clinical Specimens prior to Genotyping of HPV DNA via Consensus PCR. *Journal of Clinical Microbiology* 49: 3977-3979, 2011.

Richardson LA(§), Tota J, **Franco EL**(*). Optimizing Technology for Cervical Cancer Screening in High-Resource Settings. *Expert Review of Obstetrics & Gynecology* 6: 343-353, 2011.

Fernandez C, Fraser G, **Freeman C**, Grunfeld E, Gupta A, Mery L, Schacter B. Principles and recommendations for the provision of health care in Canada to AYAs with cancer and survivors of childhood cancer. *Journal of Adolescent and Young Adult Oncology* 2011; 1:53-59

Hasan A, Palumbo M, Atkinson J, Carret AS, **Farmer J-P**, **Montes J**, Saint-Martin C, **Freeman CR**. Treatment-related morbidity in atypical teratoid/rhabdoid tumor: multifocal necrotizing leukoencephalopathy. *Ped Neurosurgery* 2011; 47:7-14

Wong P, **Lambert C**, **Agnihotram RV**, **David M**, **Duclos M**, **Freeman CR**. Ductal carcinoma in situ. The influence of the radiotherapy boost on local control. *International Journal of Radiation Oncology Biology and Physics* 2011; epub ahead of print

Gagnon B, Low NC. Atypical migraine manifesting as mania. *J Neuropsychiatry Clin Neurosci* 23:2, Spring 2011

Hagen NA, **Lapointe B**, Ong-Lam M, Dubuc B, Walde D, **Gagnon B**, Love R, Goel R, Hawley P, Noc AH, du Souich P. A multicenter, open-label, safety and efficacy study of tetrodotoxin or cancer pain. *Curr Oncol.* 2011 Jun;18(3):e109-16

Galanakis C, Mayo N, **Gagnon B** Assessing the Role of Hydration in Delirium at the End of Life *Curr Opin Support Palliat Care.* 2011 Jun; 5(2):169-73

Liu X., Nugoli M., Laferrière J*, Saleh SM, Rodrigue-Gervais IG, Saleh M., **Park M.**, Hallett M., Muller W., **Giguère V**. Stromal retinoic acid receptor β promotes mammary gland tumorigenesis. *Proc. Natl. Acad. Sci. USA.* 2011 Jan 11; 108(2):774-9.

Villeneuve P, **Goldberg MS**, Burnett, RT, van Donkelaar A, Chen H, Martin R V. Associations between cigarette smoking, obesity, sociodemographic characteristics and remote-sensing-derived estimates of ambient PM2.5: results from a Canadian population-based survey. *Occup Environ Med* 68(12):920-7.

Goldberg, MS, Silbergeld, Ellen. On multiple comparisons and on the design and interpretation of epidemiological studies of many associations. *Environmental Research*, 2011;111:1007-9. (This is an editorial that I and my Co-Editor in Chief of the journal wrote.)

Goldberg, MS, Gasparini, A, Armstrong, B, Valois, M-F. The short-term influence of temperature on daily mortality in the temperate climate of Montreal, Canada. *Environmental Research*, 2011;111:853–860

DiFabio F, Lykoudis P, **Gordon PH**. Thromboembolism in Inflammatory bowel Disease: an Insidious Association Requiring a High Degree of Vigilance. *Semin Thromb Hemost* 2011Apr;37(3):220-5 Epub 2011 Mar 31 Review

Perri T, Korach J, **Gotlieb WH**, Beiner M, Meirou D, Friedman E, Ferenczy A, Ben-Baruch G. Prolonged conservative treatment of endometrial cancer patients: more than 1 pregnancy can be achieved. *Int J Gynecol Cancer*. 2011 Jan;21(1):72-8.

Chen X, Zhang H, Aravindakshan JP, **Gotlieb WH**, Sairam MR Anti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization. *Oncogene*. 2011 30 (25): 2874-87

Yasmeen A, Beauchamp MC, Piura E, Segal E, **Pollak M, Gotlieb WH** Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. *Gynecol Oncol*. 2011 121 (3) 492-8

Badawy M, Bêique F, Al-Halal H, Akkour K, Azar T, Lau S, **Gotlieb WH**. Anesthetic considerations and Safety of Robotic Surgery in Gynecologic Oncology *J Robot Surg* 2011 5: 235-239

Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, **Gotlieb WH**, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. *J Clin Oncol*. 2011 Aug 20;29(24):3278-85.

Segal ED, Yasmeen A, Beauchamp MC, Rosenblatt J, **Pollak M, Gotlieb WH**. *Biochem Biophys Res Commun*. 2011 Oct 2. [Epub ahead of print] Relevance of the OCT1 transporter to the antineoplastic effect of biguanides.

Gotlieb WH, Amant F, Advani F, Goswami C, Hirte H, Provencher D, Somani D, Yamada D, Tamby J, Vergote I. Intravenous aflibercept (VEGF Trap) for the treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer : results of a phase II, randomized, double-blind, placebo-controlled study. *Lancet Oncology* (Early Online Publication). 2011;doi:10.1016/S1470-2045(11)70338-2)

P Rahman, NM Roslin, M Lemire, **CMT Greenwood**, J Beyene, A Pope, L Peddle, AD Paterson, M Uddin, DD Gladman (2011). High resolution mapping in the MHC region identifies multiple independent novel loci for psoriatic arthritis. *Annals of the Rheumatic Diseases*. 70(4):690-4. [Epub 2011 Jan 17].

JM McCuaig, **C Greenwood**, C Shuman, D Chitayat, J Murphy, B Rosen, SR Armel (2011). Breast and ovarian cancer: the forgotten paternal contribution. *Journal of Genetic Counselling*. 20 (5): 442-449. [Epub April 19, 2011].

CMT Greenwood, AD Paterson, L Linton, IL Andrulis, C Apicella, A Dimitromanolakis, V Kriukov, LJ Martin, A Salleh, E Samiltchuk, RV Parekh, MC Southey, EM John, JL Hopper, NF Boyd, JM Rommens (2011). A genome-wide linkage study of mammographic density, a risk factor for breast cancer. *Journal of Breast Cancer Research*. 2011 Dec 21;13(6):R132. [Epub ahead of print]

Lara Abdul-Sater, **Melissa Henry, PhD**, Agnieszka Majdan, MD, Tamara Mijovic, MD, Jason H. Franklin, MD, **Michael P. Hier, MD**, Richard J. Payne, MD, What Are Thyroidectomy Patients Really Concerned About?; *Otolaryngology Head Neck; Surgery*, Volume 144 (5) 685-690 May 2011

Sabrina Daniela da Silva, Alfio Ferlito, Robert P. Takes, Ruud H. Brakenhoff, MeV Dominguez Valentin, Julia A. Woolgar, Carol R. Bradford, Juan P. Rodrigo, Alessandra Rinaldo, **Michael P. Hier**, Luiz P. Kowalski, Advances and applications of oral cancer basic research. *Oral Oncology* 2011; 47: 783-791

Hadi A. Al-Hakami, William Makis, Sumeet Anand, Alex Mlynarek, Martin J. Black, Jerry Stern, Richard J. Payne, and **Michael P. Hier**. Head and Neck Incidentalomas on Positron Emission Tomographic Scanning: Ignore or Investigate? *Journal of Otolaryngology-Head and Neck Surgery*, Vol 40, No 5, October 2011:pp 384-390

Alexander Amir, Shawn Karls, Noah Sands, Véronique-Isabelle Forest, **Michael P. Hier**, Olga Gologan, and Richard Payne. Value of Thyroid Incidentalomas on Positron Emission Tomographic Scans among Thyroidectomy Patients. *Journal of Otolaryngology-Head and Neck Surgery*, Vol 40, No 5, October 2011:pp 391-395

L. Caussa, **T. Hijal**, J. Michon and S. Helfre, Role of palliative radiotherapy in the management of metastatic pediatric neuroblastoma: a retrospective single institution study, *Int J Radiat Oncol Biol Phys*. 2011 Jan 1;79(1):214-9.

Al-Halabi H, Nantel A, Klekner A, Guiot MC, Albrecht S, Hauser P, Garami M, Bognar L, Kavan P, Gerges N, Shirinian M, **Roberge D, Muanza T, Jabado N**. Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma. *Acta Neuropathol*. 2011 Feb;121(2):229-39.

Wing, S.S., S.H. Lecker, **Jagoe, R.T.** Proteolysis in illness-associated skeletal muscle atrophy: from pathways to networks. *Crit Rev Clin Lab Sci* 2011 1-22.

Bashashati A,* **Johnson NA***, Khodabakhshi AH, Whiteside MD, Zare H, Scott DW, Lo K, Gottardo R, Brinkman FSL, Connors JM, Slack JW, Gascoyne RD, Weng AP, Brinkman RR. B-cells with high side scatter parameter by flow cytometry correlate with inferior survival in

diffuse large B cell lymphoma. Accepted in American Journal of Clinical Pathology on November 16th 2011. * **contributed equally as first authors**

Schuetz JM, **Johnson NA***, Morin RD, Scott DW, Tan K, Ben-Nierah S, Boyle M, Slack GW, Marra MA, Connors JM, Brooks-Wilson AR and Gascoyne RD. BCL2 mutations in diffuse large B-cell lymphoma. *Leukemia*. 2011 Dec 22. doi: 10.1038/leu.2011.378. [Epub ahead of print] * **contributed equally as first authors**

Singh RR, Ben-Neriah S, **Johnson NA**, Connors JM, Gascoyne RD, Horsman DE. Identification of a novel non-immunoglobulin/MYC translocation t(8;12)(q24;p12) involving the LRMP gene in a primary B-cell lymphoma. A case report. *Leuk Res*. 2011 Oct 11. [Epub ahead of print]

Iqbal J, Meyer PN, Smith L, **Johnson NA**, Vose JM, Greiner TC, Connors J, Staudt LM, Rimsza LM, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook J, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan W. BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-Cell Lymphoma Treated with CHOP-like therapy and Rituximab. *Clin Cancer Res*. 2011 Sep 20.

Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, **Johnson NA**, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. *Nature*. 2011 Jul 27. doi: 10.1038/nature10351. [Epub ahead of print]

Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, **Johnson NA**, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA, Gascoyne RD. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. *Nature*. 2011 Mar 17;471(7338):377-81. Epub 2011 Mar 2.

Körner, A. & Fritzsche, K. (2011). Psychosomatic Services for Melanoma Patients in Tertiary Care. *International Journal of Dermatology*. Doi: 10.1111/j/1365-4632.2011.05228.x.

Thombs, B.D., & **Körner, A.** (2011, e-first). Is there Evidence that Depression Screening Benefits Patients with Chronic Medical Illness? Not yet. [German]. *Nervenarzt*. DOI 10.1007/s00115-011-3281-z. [e-Pub ahead of print].

Ernst J., Weissflog, G., Brähler, E., Niederwieser, D., **Körner, A.**, Schröder, C. (2011). Participation of haemato-oncological patients in medical decision-making and their confidence in decisions. *European Journal of Cancer Care*, 20(4), 534–538.

Perry, J.C., & **Körner, A.** (2011). Impulsive phenomena, the impulsive character and DSM personality disorders. *Journal of Personality Disorders*. 25(5), 586-606.

Barthel, Y., Ernst, J., Rawohl, S., **Körner, A.**, Lehmann, A., & Brähler, E. (2011). Psychosocial situation of students – need for counseling and interest in psychotherapy [German]. *Zeitschrift für Psychotraumatologie, Psychotherapiewissenschaft und Psychologische Medizin*. 2, 73-83.

Körner, A., Augustin, M., & Zschocke, I. (2011). Health behaviors of skin cancer patients in melanoma follow-up care [German]. *Zeitschrift für Gesundheitspsychologie*, 19(1), 2-12.

Drapeau, M., Perry, J.C., & **Körner, A.** (2011). Interpersonal behaviors and BPD. Are specific interpersonal behaviors related to borderline personality disorder? An empirical study using the Core Conflictual Relationship Theme standard categories. *Archives of Psychiatry and Psychotherapy*, 3, 5-10.

Drapeau, M., DeRotin, Y., Blake, E., Beretta, V., Strack, M., **Körner, A.**, et al. (2011). Defensive flexibility and its relation to symptom severity, depression and anxiety. *The Journal of Nervous and Mental Disease*, 199(1), 38-41

Hagen NA, **Lapointe B**, Ong-Lam M, et alii. A multicentre open-label safety and efficacy study of Tetrodotoxin for Cancer Pain. *Current Oncology*, 2011, Volume 18, Number 3, 109-116.

Lau S, Buzaglo K, Vaknin Z, Brin S, Kaufer R, Drummond N, Gourdji I, **Aubin S**, **Rosberger Z**, **Gotlieb WH**. Relationship between body mass index and robotic surgery outcomes of women diagnosed with endometrial cancer. *Int J Gynecol Cancer* 2011 21 (4) 722-9

Shirley Lehnert, Yongbiao Li, Ed Bump, Bill Riddoch, Abdellatif Chenite and Matthew Shive.. 125I-Iododeoxyuridine for the Treatment of a Brain Tumor Model: Selection of Conditions for Optimal Effectiveness. *The Open Nuclear Medicine Journal*, 2011, 3, 19-24

Loiselle, C. G. & Sterling, M. (2011, published online before print). Views on death and dying among health care workers in an Indian cancer care hospice: Balancing individual and collective needs and perspectives. *Palliative Medicine*. doi: 10.1177/0269216311400931

Strohschein, F.J., Bergman, H., Carnevale, F.A., & **Loiselle, C.G.** (2011). Patient Decision Making Among Older Individuals With Cancer. *Qualitative Health Research* 21(7), 900-926. doi: 10.1177/1049732311399778.

Fearon KCH, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, **MacDonald N**, Mantovani G, Davis M, Muscaritoli M, Ottery FD, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE, Conceptual framework for the definition and classification of cancer cachexia: an international consensus statement, *Lancet Oncol* 2011; 12:489-495.

Brisbois Clarkson T, de Kock IH, Watanabe S, Mirhosseini M, Lamoureux D, Chasen M, **MacDonald N**, Baracos VE, Wismer WV. Delta-9-tetrahydrocannabinol may be useful to palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. *Ann Oncol* 2011;22(9):2086-2093.

MacDonald N. Chronic inflammatory states: their relationship to cancer prognosis and symptoms. *J R Coll Physicians Edinb* 2011; 41:246-252.

M Lemaire, CA Lemarie, M Flores Molina, E Schiffrin, S Lehoux, and **KK Mann**. Exposure to Environmentally-Relevant Arsenic Concentrations Increases Atherosclerosis in ApoE^{-/-} Mouse Model. *Toxicological Sciences* 122(1): 211-21, 2011. (IF = 5.093)

S Yanik, A Haas, **KK Mann**, and JJ Schlezinger. Organotins are potent activators of PPAR γ and adipocyte differentiation in bone marrow multipotent mesenchymal stromal. *Toxicological Sciences Toxicol Sci.* 122(2):476-88, 2011. (IF= 5.093)

C Guilbert, ADR Kelly, LA Petrucci, M Lemaire, and **KK Mann**. Exposure to tungsten induces DNA damage and apoptosis in developing B lymphocytes. *Leukemia* 25(12):1900-4, 2011. (IF = 8.966)

McCaffrey, L.M. and Macara, I.G. (2011). Epithelial Organization, Cell Polarity, and Tumorigenesis. *Trends Biochem Sci.* Dec 21(12):727-35

Jamal M.H., Rousseau M.C., Hanna W., Doi S.A., **Meterissian S.** and Snell L. 2011 Effect of the ACGME duty hours restrictions on surgical residents and faculty: a systematic review *Academic Medicine* 86: 34-42

Sudarshan M., **Meguerditchian AN.**, Mesurolle B. and **Meterissian S.** 2011 Flat epithelial atypia of the breast: characteristics and behaviors *Am. J. Surg.* 201: 245-250.

Jamal M., Rayment J., **Meguerditchian AN.**, Doi S.A.R. and **Meterissian S.** 2011 Impact of the sentinel node frozen section result on the probability of additional nodal metastases as predicted by the MSKCC nomogram in breast cancer. *Japanese Journal of Clinical Oncology* 41: 314-319

Meguerditchian A.N., **Meterissian S.H.** and Dunn K.B. 2011 Anorectal melanoma: diagnosis and treatment *Dis. Colon Rectum*; 54: 638-44

Aguilar M., **Meterissian S.**, Levesque S. and Andonian S. 2011 Nephrectomy in patients with Caroli's and ADPKD may be associated with increased morbidity *Can. Urol. Assoc. J.*;5:E19-22

Skrutkowski M., Saucier A. and **Meterissian S.** 2011 The breast cancer patient navigation kit: development and user feedback. *J. Cancer Educ.* Apr 3 (Epub ahead of print)

Nassif M., Ameer A., **Meterissian S.** and **Meguerditchian A.N.** 2011 Unresectable rectal necrosis *Case Reports in Medicine* 212840, Epub 2011 May 5th

Mesurrolle B., Solorzano S., Kao E., Aldis A., El-Khoury M. and **Meterissian S.** 2011 Flat epithelial atypia of the breast: pathological-radiological correlation. *American Journal of Roentgenology* 197:740-6

Pettersson F, **Miller WH Jr**, Nervi C, Gronemeyer HJ, Licht J, Tallman MS, Waxman S. The 12th international conference on differentiation therapy: targeting the aberrant growth, differentiation and cell death programs of cancer cells. *Cell Death Differ*, 18:1231-33, 2011.

Pettersson F, Yau C, Dobocan M C, Culjkovic-Kraljacic B, Retrouvay H, Puckett R, Ludmila M. Flores, Ian E. Krop, Caroline Rousseau, E Cocolakis, K L B Borden, Benz CC, and **Miller WH, Jr.** Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. *Clinical Cancer Research*, Cancer Res 17(9):2874-84, 2011.

Petrucelli L A, Dupéré-Richer D, Pettersson F, Retrouvey H, Skoulikas S, **Miller WH Jr.** Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells. *PLoS ONE* 6(6): e20987. doi:10.1371/journal.pone.0020987, June 2011.

Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, **Miller WH Jr**, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, and Wolchok J D. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. *The New England Journal of Medicine*, 364(26):2517-26, 2011.

Soye KJ, Trottier C, Richardson CD, Ward BJ, and **Miller WH Jr.** RIG-I Is Required for the Inhibition of Measles Virus by Retinoids. *PLoS One* 2011;6(7):e22323. [Epub 2011 Jul 19].

Hanna WC, **Ferri LE**, McKendy KM, **Turcotte RE**, Sirois C, **Mulder DS.** Reconstruction after major chest wall resection: Can rigid fixation be avoided? *Surgery* 2011 Oct; 150(4):590-7.

Paliouras M, Zaman N, Lumbroso R, Kapogeorgakis L, Beitel LK, Wang E, Trifiro M. 2011. Dynamic rewiring of the androgen receptor protein interaction network correlates with prostate cancer clinical outcomes. *Integrative Biology*, 2011.

Davidson D, Coulombe Y, Martinez-Marignac VL, Amrein L, Grenier J, Hodgkinson K, Masson JY, **Aloyz R**, **Panasci LC.** Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. *Invest New Drugs*.. PMID: 21221710 Jan 1, 2011.

Amrein L, Davidson D, Shawi M, Petrucelli L, Miller W, **Aloyz R** and **Panasci LC.** Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy . *Leuk Res.* 2011 Aug;35(8):1080-6
Ferrario C, Wong A, Gao T, Bouganim N, **Aloyz R**, **Panasci LC.** Trastuzumab and vinorelbine in early stages of HER2-positive breast cancer. *J Chemother.* 2011 Feb;23(1):32-5

Hebb, J; **Assouline, S**; Rousseau, C **Aloyz, R**; DesJardins, P; Caplan,S; Egorin, M; Amrein, L; **Panasci, L** A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. *Cancer Chemother Pharmacol.* 2011 Sept 68(3):643-51

Davidson D, Grenier J, Martinez-Marignac V, Amrein L, Shawi M, Tokars M, **Aloyz R, Panasci L**. Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells. *Invest New Drugs.* 2011 May 13. [Epub ahead of print]

Amrein L, Zakaria R, Bertrand J, Aloyz R, **Panasci L** ZRF4, a combi-molecule with increased efficacy as compared to the individual components in Chronic Lymphocytic Leukemia lymphocytes *in vitro* Leukemia. 2011 Sep;25(9):1512-6

Sahebjam S, **Aloyz R**, Pilavdzic D, Brisson ML, Ferrario C, Bouganim N, **Cohen V, Miller WH Jr, Panasci LC** Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. *Br J Cancer.* 2011 105:1342-5.

Parachoniak CA, Lui Y, Abella JV, Keen JH and **Park M**. GGA3 Functions as a Switch to Promote Met Receptor Recycling, Essential for Sustained ERK and Cell Migration. *Developmental Cell.* 2011 Jun 14; 20(6):751-63.

Cheng B, Ling C, Dai Y, Lu Y, Glushakova LG, Gee SWY, McGoogan KE, Aslanidi GV, **Park M**, Stacpoole PW, Siemann D, Liu C, Srivastava A, Ling C. Development of optimized AAV3 serotype vectors: Mechanism of high-efficiency transduction of human liver cancer cells. *Gene Therapy.* Epub 21 July 2011; doi: 10.1038/gt.2011.105.

Bertos NR, **Park M**. Breast cancer - one term, many entities? *J Clin Invest.* 2011 Oct 3;121(10):3789-96. Epub 2011 Oct 3. Review.

Sangwan V, Abella J, Lai A, Bertos N, Stuible M, **Tremblay ML, Park M**. Protein tyrosine phosphatase PTP1B modulates early endosome fusion and trafficking of Met and EGF receptor tyrosine kinases. *J Biol Chem.* 2011 Nov 1. [Epub ahead of print] PubMed PMID: 22045810.

Pla-Roca M, Leulmi RF, Tourekhanova S, Bergeron S, Laforte V, Moreau E, Gosline SJC., Bertos N, Hallett M, **Park M**, Juncker D. Antibody Colocalization Microarray: A Scalable Technology for Multiplex Protein Analysis in Complex Samples. *Molecular and Cellular Proteomics.* mcp.M111.011460. First Published on December 14, 2011, doi:10.1074/mcp.M111.011460.

Ravindar, K., Reddy, M.S., Lindqvist, L., **Pelletier, J.**, and Deslongchamps, P. (2011). Synthesis of the antiproliferative agent hippuristanol and its analogues via Suárez cyclizations and Hg(II)-catalyzed spiroketalizations. *J. Org. Chem.* 76: 1269-1284.

Cencic, R., Hall, D.R., Robert, F., Du, Y., Min, J., Li, L., Qui, M., Lewis, I., Kurtkaya, S., Dingleline, R., Fu, H., Kozakov, D., Vadja, S., and **Pelletier, J.** (2011). Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. *PNAS* 108: 1046-1051

Takacs, J.E., Neary, T.B., Ingolia, N.T., Martin-Marcos, P., Weissman, J.S., **Pelletier, J.**, Hinnebusch, A.G., and Lorsch, J.R (2011). Identification of compounds that decrease the fidelity of start codon recognition by the eukaryotic translational machinery. *RNA* 17: 439-452.

Huang, S-X., Zhao, L-X., Jiang, C-J., Duan, Y., Roberts, F., **Pelletier, J.**, and Shen, B. (2011) Cycloheximide and congeners, inhibitors of eukaryotic protein synthesis, from *Streptomyces* sps. YIM56141 and 56132. *J. Antibiotics*. 64: 163-166.

Warr, M.R., Mills, J.R., Nguyen, M., Lemaire-Ewing, S., Baardnsnes, J., Sun, K.L.W., Malina, A., Young, J.C., Jeyaraju, D.V., O'Connor-McCourt, M., Pellegrini, L., **Pelletier, J.**, and Shore, G. (2011). Mitochondrial-dependent N-terminal Processing of Outer Membrane Mcl-1 Removes an Essential Mule/Las1 Binding Site. *J. Biol. Chem.* 286: 25098-25107.

Cencic R, Desforges M, Hall DR, Kozakov D, Du Y, Min J, Dingleline R, Fu H, Vajda S, Talbot PJ, **Pelletier J.** (2011) Blocking eIF4E:eIF4G interaction as a strategy to impair coronavirus replication. *J. Virol.* 85: 6381-6389.

Dauber B, **Pelletier J.**, Smiley JR. (2011). The Herpes Simplex Virus 1 vhs protein enhances translation of viral true late mRNAs and virus production in a cell type-dependent manner. *J. Virol.* 85: 5363-5373.

Konicek, B.W., Stephens, J.R., McNulty, A.M., Robichaud, N., Peery, R.B., Dumstorf, C.A., Dowless, M.S., Iversen, P.W., Parsons, S., Ellis, K.E., McCann, D.J., **Pelletier, J.**, Furic, L., Yingling, J.M., Stancato, J.F., Sonenberg, N., and Graff, J.R. (2011). Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastasis. *Cancer Res.* 71: 1849-1857.

Wahba, A.S., Azizi, F., Deleavey, G.F., Brown, C., Robert, F., Carrier, M., Kalota, A., Gewirtz, A.M., **Pelletier, J.**, Hudson, R.H.E., and Damha, M.J. (2011). Phenylpyrrolocytosine as an unobtrusive base modification for monitoring activity and cellular trafficking of siRNA. *ACS Chem. Biol.* 6: 912-919.

Schatz, J.H., Oricchio, E., Jiang, M., Linkov, I., Maragulia, J., Shi, W., Zhang, Z., Zelenetz, A., Teruya-Feldstein, J., **Pelletier, J.**, and Wendel, H.-G. (2011) Therapeutic inhibition of cap-dependent translation coordinately blocks redundant AKT and PIM kinase signals in lymphoma. *J. Exp. Med.* 208:1799-1807.

Kozakov, D., Hall, D.R., Chuang, G.-Y., Cencic, R., Brenke, R., Beglov, D., **Pelletier, J.**, Whitty, A., and Vadja, S. (2011) Hot spot conservation and druggable sites in protein-protein interfaces. *PNAS.* 108: 13528-13533.

Rodrigo, C.M., Cencic, R., Roche, S.P., **Pelletier, J.** and Porco Jr., J.A. (2011). Synthesis of Rocaglamides and related compounds as protein translation inhibitors: Synthetic and biological studies. *J. Med. Chem.* OnLine.

Robert, F., Mills, J., Agenor, A., Wang, D., Di Marco, S., Cencic, R., Tremblay, M., Gallouzi, I.E., Hekimi, S., Wing, S.S., and **Pelletier, J.** (2011). Targeting tumor-driven protein synthesis in Anorexia-Cachexia syndrome delays onset and prolongs survival. *Cancer Research.* On Line.

Fred, R.G., Sandberg, M., **Pelletier, J.**, and Welsh, N. (2011). The human insulin mRNA is partly translated via a cap-and eIF4A-independent mechanism. *Biochem Biophys Res Commun.* 12: 693-698.

Roberge D, Skamene T, **Turcotte R,** Powell T, Saran N, **Freeman C.** Inter- and intra-observer variation in soft-tissue sarcoma target definition. *Cancer Radiother.* 2011; 15:421-425

Alexander, E. Soisson, **T. Hijal,** A. Sarhefnia and **J. Seuntjens,** Comparison of modulated electron radiotherapy to conventional electron boost irradiation and volumetric modulated photon arc therapy for treatment of tumour bed boost in breast cancer, *Radiother Oncol.* 2011 Aug;100(2):253-8.

H. Bouchard, **J. Seuntjens,** I. Kawrakow (2011) A Monte Carlo method to evaluate the impact of positioning errors on detector response and quality correction factors in nonstandard beams, *Phys. Med. Biol* 56, 2617-2634.

Cherpak, M. Serban, **J. Seuntjens,** J. Cygler (2011) 4D dose-position verification in radiation therapy using the RADPOS system in a deformable lung phantom, *Med. Phys.* 38, 179-187.

R. Al-Wassia, A. Dal Pra, K. Shun, A. Shaban, C. Corriveau, C. Edelstein, J. Deschenes, R. Ruo, **H. Patrocinio, F. L B Cury, F. DeBlois, George Shenouda,** “Stereotactic Fractionated Radiotherapy in the Treatment of Juxtapapillary Choroidal Melanoma: The McGill University Experience”, *Int J Radiat Oncol Biol Phys* vol. 81 (4) pp. e455-62, (2011)

Hashem R, Tanzer M, Rene N, **Evans M, Souhami L.** Post operative radiation therapy after hip replacement in High risk patients for development of heterotopic bone formation. *Cancer Radioth* 15:261-264, 2011.

Dal Pra A, **Cury FL, Souhami L.** Radiation therapy and androgen deprivation in the management of high risk prostate cancer. *Braz Int J Urol* 37:161-179, 2011.

Yafi FA, **Duclos M,** Correa JA, **Tanguay S, Aprikian AG, Cury F, Souhami L, Rajan R,** Kassouf W. Contemporary outcome and management of patients who had an aborted cystectomy due to unresectable bladder cancer. *Urol Oncol.* 29:309-13, 2011

Siker ML, Wang M, Porter K, Nelson DF, Curran WJ, Michalski JM, **Souhami L**, Chakravati A, Yung WK, Delrowe J, Coughlin CT, Mehta MP. Age as an independent prognostic factor in patients with glioblastoma: a Radiation Therapy Oncology Group and American College of Surgeons National Cancer data comparison. *J Neurooncol* 104:351-356, 2011.

Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Leibenhaut MH, Husain SM, Rotman M, **Souhami L**, Sandler HM, Shipley WU. Radiotherapy plus Short-Term Androgen Deprivation Therapy for Localized Adenocarcinoma of the Prostate: Results of RTOG 9408. *N Engl J Med* 365:107-118, 2011.

Al Hinai Q, Tampieri D, **Souhami L**, Sadikot A, Sinclair D, Leblanc R. Cyst formation following radiosurgery for AVMs: report on 3 cases. *Can J Neurol Sci* 38:734-740, 2011.

Lawrence YR, Wang M, Dicker AP, Andrews D, Curran WJ Jr, Michalski JM, **Souhami L**, Yung WK, Mehta M. Early toxicity predicts long-term survival in high-grade glioma. *Br J Cancer* 104:1365-1371, 2011.

Wong P, **Muanza T**, Reynard E, Robert K, Barker J, **Sultanem K**. *Int J Radiat Oncol Biol Phys*. 2011 Jan 1;79(1):39-45. Epub 2010 Jul 10.

Nishimori H, **Tabah R**, Hickeson M, How J. Incidental thyroid 'PETomas': clinical significance and novel description of the self-resolving variant of focal FDG-PET thyroid uptake. *Can J Surg* 54(2): 83-88 (2011).

Ben Amor IM, Edouard T, Glorieux FH, Chabot G, **Tischkowitz M**, Roschger P, Klaushofer K, Rauch F. Low bone mass and high material bone density in two patients with Loeys-Dietz syndrome caused by transforming growth factor receptor 2 mutations. *J Bone Miner Res*. 2011 Nov 16. doi: 10.1002/jbmr.1470 (early online publication).

Gelmon KA, **Tischkowitz M**, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol*. 2011 Sep;12(9):852-61

Villeneuve H, Tremblay S, **Galiatsatos P**, Hamel N, Guertin L, Morency R, **Tischkowitz M**. Acinic cell carcinoma of the retromolar trigone region: expanding the tumor phenotype in Cowden syndrome? *Familial Cancer*. 2011 Dec;10(4):691-4.

Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Barile M, Pensotti V, Pasini B, Dolcetti R, Giannini G, Putignano AL, Varesco L, Radice P, Mai PL, Greene MH, Andrulis IL, Glendon G, Ozelik H; Ontario Cancer Genetics Network, Thomassen M, Gerdes AM, Kruse TA, Jensen UB, Crüger DG, Caligo MA, Laitman Y, Milgrom R, Kaufman B, Paluch-Shimon S, Friedman E, Loman N, Harbst K, Lindblom A, Arver B, Ehrencrona H, Melin B; SWE-BRCA, Nathanson KL, Domchek SM, Rebbeck T, Jakubowska A, Lubinski J, Gronwald J, Huzarski T,

Byrski T, Cybulski C, Gorski B, Osorio A, Cajal TR, Fostira F, Andrés R, Benitez J, Hamann U, Hogervorst FB, Rookus MA, Hooning MJ, Nelen MR, van der Luijt RB, van Os TA, van Asperen CJ, Devilee P, Meijers-Heijboer HE, Gómez Garcia EB; HEBON, Peock S, Cook M, Frost D, Platte R, Leyland J, Evans DG, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Eccles D, Ong KR, Cook J, Douglas F, Paterson J, Kennedy MJ, Miedzybrodzka Z; EMBRACE, Godwin A, Stoppa-Lyonnet D, Buecher B, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Lasset C, Leroux D, Faivre L, Bronner M, Prieur F, Nogues C, Rouleau E, Pujol P, Coupier I, Frénay M; GEMO Study Collaborators, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D; Breast Cancer Family Registry, Singer CF, Tea MK, Pfeiler G, Dressler AC, Hansen TV, Jønson L, Ejlertsen B, Barkardottir RB, Kirchhoff T, Offit K, Piedmonte M, Rodriguez G, Small L, Boggess J, Blank S, Basil J, Azodi M, Toland AE, Montagna M, Tognazzo S, Agata S, Imyanitov E, Janavicius R, Lazaro C, Blanco I, Pharoah PD, Sucheston L, Karlan BY, Walsh CS, Olah E, Bozsik A, Teo SH, Seldon JL, Beattie MS, van Rensburg EJ, Sluiter MD, Diez O, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ruehl I, Varon-Mateeva R, Kast K, Deissler H, Niederacher D, Arnold N, Gadzicki D, Schönbuchner I, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Dumont M, Chiquette J, **Tischkowitz M**, Chen X, Beesley J, Spurdle AB; kConFab investigators, Neuhausen SL, Ding YC, Fredericksen Z, Wang X, Pankratz VS, Couch F, Simard J, Easton DF, Chenevix-Trench G; on behalf of CIMBA. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Hum Mol Genet.* 2011 20(16):3304-3321

Stadler ZK, Salo-Mullen E, Sabbaghian N, Simon JA, Zhang L, Olson SH, Kurtz R, Offit K, **Foulkes WD**, Robson ME, **Tischkowitz M**. Germline PALB2 mutation analysis in breast-pancreas cancer families. *J Med Genet.* 2011;48(8):523-5.

Tischkowitz M, Winqvist R. Using mouse models to investigate the biological and physiological consequences of defects in the Fanconi anaemia/breast cancer DNA repair signalling pathway. (invited commentary) *J Pathol.* Jul;224(3):301-5

Karalis A, **Tischkowitz M**, Millington WM. Dermatological Manifestations of Inherited Cancer Syndromes in Children. *Br J Dermatol.* 2011 Feb;164(2):245-56.

AH Birch, SL Arcand, KK Oros, K Rahimi, AK Watters, D Provencher, **CM Greenwood**, AM Mes-Masson, **PN Tonin** (2011). Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. *PLoS One.* 6(12): e28250. doi:10.1371/journal.pone.0028250.

Jaramillo M, Gomez MA, Larsson O, Shio MT, **Topisirovic I**, Contreras I, Luxenburg R, Rosenfeld A, Colina R, McMaster RW, Olivier M, Costa-Mattioli M, Sonenberg N. (2011) Leishmania Repression of Host Translation through mTOR Cleavage Is Required for Parasite Survival and Infection. *Cell Host Microbe.* 9(4):331-41.

Topisirovic I, Sonenberg N. Translational control by the eukaryotic ribosome. (2011) *Cell* 145(3):333-4.

Julien SG, Dubé N, Hardy S, **Tremblay ML**. Inside the human cancer tyrosine phosphatome. *Nat Rev Cancer*. 2011 Jan;11(1):35-49. Review.

Martin KR, Xu Y, Looyenga BD, Davis RJ, Wu CL, **Tremblay ML**, Xu HE, MacKeigan JP. Identification of PTPsigma as an autophagic phosphatase. *J Cell Sci*. 2011 Mar 1;124(Pt 5):812-9. Epub 2011 Feb 8.

Raven JF, Williams V, Wang S, **Tremblay ML**, Muller WJ, Durbin JE, Koromilas AE. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. *Cell Cycle*. 2011 Mar 1;10(5):794-804.

El-Kouhen K, **Tremblay ML**. PTPMT1: Connecting Cardiolipin Biosynthesis to Mitochondrial Function. *Cell Metab*. 2011 Jun 8;13(6):615-7.

Sangwan V, Abella J, Lai A, Bertos N, Stuibler M, **Tremblay ML**, Park M. Protein-tyrosine phosphatase 1B modulates early endosome fusion and trafficking of Met and epidermal growth factor receptors. *J Biol Chem*. 2011 Dec 30;286(52):45000-13. Epub 2011 Nov 1.

Wiede F, Shields BJ, Chew SH, Kyriakopoulos K, van Vliet C, Galic S, **Tremblay ML**, Russell SM, Godfrey DI, Tiganis T. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. *J Clin Invest*. 2011 Dec;121(12):4758-74. 10.

Moreau LC, **Turcotte R**, Ferguson P, Wunder J, Clarkson P, Masri B, Isler M, Dion N, Werier J, Ghert M, Dehesi B; the Canadian Orthopaedic Oncology Society (CANOOS). Myxoid Round Cell Liposarcoma (MRCLS) Revisited: An analysis of 418 Primarily Managed Cases. *Ann Surg Oncol*. 2011 Nov 4. [Epub ahead of print].

Biau DJ, Ferguson PC, **Turcotte RE**, Chung P, Isler MH, Riad S, Griffin AM, Catton CN, O'Sullivan B, Wunder JS. Adverse effect of age on the recurrence of soft tissue sarcoma of the extremity and trunk. *J Clin Oncol*. 2011 Oct 20;29(30):4029-35.

Riad S, Biau D, Holt GE, Werier J, **Turcotte RE**, Ferguson PC, Griffin AM, Chung PW, Catton CN, O'Sullivan B, Wunder JS. The Clinical and Functional Outcome for Patients with Radiation-Induced Soft-Tissue Sarcoma (Cancer Pubmed Oct 2011).

Yoon J, Al Shafai L, Nahal A, **Turcotte RE**, Martin MH. Melorheostosis of the sacrum causing acute-onset neurological symptoms. *Skeletal Radiol*. 2011 Jun 12. [Epub ahead of print].

Mak IW, Cowan RW, **Turcotte RE**, Singh G, Ghert M. PTHrP Induces Autocrine/Paracrine Proliferation of Bone Tumor Cells through Inhibition of Apoptosis. *PLoS One* 2011;6(5):199975.

Singh S, Mak I, Cowan RW, **Turcotte R**, Singh G, Ghert M. The role of TWIST as a regulator in giant cell tumor of bone. *J Cell Biochem*. 2011 Sep;112(9):2287-95.

Mak IW, **Turcotte RE**, Popovic S, Singh G, Ghert M. AP-1 as a regulator of MMP-13 in the stromal cell of Giant Cell Tumor of Bone. *Biochem Res Int*. 2011;2011:164197.

Friedmann D, Wunder J, Ferguson P, O'Sullivan B, **Roberge D**, Catton C, **Freeman C**, Saran N, **Turcotte R**. Incidence and severity of lymphedema following limb salvage of extremity soft tissue sarcoma. *Sarcoma* 2011; epub ahead of print

Vessela Kristensen*, Charles Vaske*, **Josie Ursini-Siegel**, Peter Van Loo, Ravi Sachidanandam , Therese Sørli , Fredrik Wärnberg , Vilde Haakensen , Aslaug Helland, Bjørn Naume , Charles Perou , David Haussler, Olga Troyanskaya and Anne-Lise Børresen-Dale. 2011. Integrated Molecular Profiles of Invasive Breast Tumors and DCISs Reveal Differential Vascular and Interleukin Signalling. **PNAS**, (PMID: 21908711) * co-first authors

Josie Ursini-Siegel. 2011. Beyond immune surveillance: Stat1 limits tumor growth in a cell autonomous fashion. **Cell Cycle**, 10: 1348.

T. Vuong, K. Waschke, **T. Niazi**, C. Richard, J. Parent, **S. Liberman**, S. Mayrand, R. Loungnarath, **B. Stein**, and **S. Devic**, The value of Botox-A in acute radiation proctitis: Results from a phase I/II study using a 3 Dimension scoring system, *Intl. J. of Radiation Oncology, Biology Physics* **80**, 1505-1511 (2011).

DiTacchio L, Le HD, Vollmers C, Hatori M, **Witcher M**, Secombe J, Panda S. Histone lysine demethylase JARID1a activates CLOCK-BMAL1 and influences the circadian clock. *Science*. 2011 Sep 30;333(6051):1881-5.

Books

Loiselle, C. G., Profetto-McGrath, J., Polit, D. F., & Beck, C.T. (2011). *Canadian essentials of nursing research*. Third Edition. New York: Wolters Kluwer Health/Lippincott, Williams & Wilkins. Peer-reviewed. 501 p.

Book Chapters

Aubin, S. (2011). Dysfonction orgasmique chez le femme: Évaluation et intervention selon l'approche TCC [Orgasmic dysfunction in women. Evaluation and intervention using the cognitive-behavioral approche]. Livre I: Bases théoriques et la prise en charge des troubles sexuels. Sexualité, couple et traitement cognitivo-comportemental[Book 1. Theoretical basis and the clinical management of sexual dysfunctions. Sexuality, couple and cognitive-behavioral therapy. Poudat, F-X, Editor, Éditions Masson/Elsevier, France.

K. Sigmundsson, **N. Beauchemin**, J. Lengqvist and B. Öbrink. Determination of binding kinetics between proteins with multiple nonidentical binding sites by SPR flow cell biosensor technology. Chapter 3, *Biosensors for Health, Environment and Biosecurity / Book 1*, editors: In Tech, 35-58 (2011).

Branton, P.E. and R. C. Marcellus. 2011. Adenoviruses, In "Fundamentals of Molecular Virology" (2nd edition). Ed. N. Acheson. John Wiley and Sons, New York, NY. pp. 274-284.

El Naqa I., Craft JM., Oh JH., Deasy JO, "Biomarkers for Early Radiation Response for Adaptive Radiation Therapy," *Adaptive Radiation Therapy* (X. Allen Li, Editor). Taylor & Francis, Chapter 4, pp. 53-68, 2011.

El Naqa I., Oh J., Yang Y., “Relevance feedback as new tool for computer-aided diagnosis in image databases,” *Machine Learning in Computer-Aided Diagnosis: Medical Imaging Intelligence and Analysis* (K. Suzuki, Editor). IGI Global, Hershey, 2011

Reiss A, **Gotlieb WH.** On the origin of ovarian and endometrial cancers: molecular profiling of gynecologic cancers. In “Recent advances in gynaecologic oncology. (2011) Jaypee brothers ,India, Dilip Kumar Dutta editor.

Reiss, **Gotlieb WH.** Molecular Basics of Gynecologic Cancers. In “Textbook of Gyneaeological Oncology”, 2nd edition (2011) ESGO, A Ayhan, N Reed and M Gultekin editors

Furic L, Livingstone, M, **Topisirovic I**, Sonenberg N (2011) Actions of Insulin As a Survival and Growth Factor: Akt, mTOR, and Regulation of Translation; in "Insulin Resistance and Cancer"; 1st edition; Fantus, I. George (Ed.), Springer ISBN 978-1-4419-9910-8.

Turcotte R.E., Roberge D., Alcindor T. Les sarcomes des parties molles. In *Thérapeutique du cancer*. 2nd edition, Morère JF, Mornex F, Soulières D. Eds. 2nd edition, Springer, Paris, 2011, 635-51.

Turcotte R.E., Alcindor T., Roberge D. Les sarcomes osseux, In *Thérapeutique du cancer*. 2nd edition, Morère JF, Mornex F, Soulières D. Eds. Eds. 2nd edition, Springer, Paris, 2011, 615-33.

Vasilevsky, CA. Anorectal Abscess & Fistula in *The ASCRS Textbook of Colorectal Surgery*, Beck DE, Roberts PL, Salarides TJ, Senagore AS, Stamos MJ, Wener SD(eds) , Spinger, New York, 2011, 2nd edition. Chapter 13, pp 219-244

Zannis-Hadjopoulos, M. and Rampakakis, E. (2011). Synergy between DNA Replication and Repair Mechanisms. Chapter for book on ‘DNA Repair/Book 1-On the Pathways to Fixing DNA Damage and Errors, ISBN 978-953-307-649-2, edited by Francesca Storici’, InTech online publishers (**Invited**)

Invited Editorials, Non-peer-reviewed Articles, Letters, Journal Supplements, Technical Reports, Reviews etc.

Franco EL (Guest Editor). Human Papillomavirus Vaccines. Future Medicine E-Book, Future Science Group, ISBN 978-1-78084-000-0, 2011

Franco EL. Foreword. Future Medicine, DOI:10.2217/EBO.11.82:2-5, 2011.

Franco EL. Commentary: Screening HPV vaccinated generations. HPV Today, No. 24, August 2011, pp. 6-7.

Malina, A., Cencic, R., and **Pelletier, J.** (2011). Targeting Translation Dependence in Cancer. *Oncotarget*. 2: 76-88.

Proceedings

Sarfehnia A, Stewart K, Ross C, McEwen M, **Seuntjens JP** (2011) Primary water calorimetry for clinical electron beams, scanned proton beams and ¹⁹²Ir brachytherapy, Proceedings of IAEA International Symposium on Standards, Applications and Quality Assurance in Medical Radiation Dosimetry, pp.87-98 (International Atomic Energy Agency, Vienna, Austria).

Bouchard H, Kawrakow I, Carrier J-F, **Seuntjens J** (2011) Conceptual improvements and limitations in nonstandard beam reference dosimetry, Proceedings of IAEA International Symposium on Standards, Applications and Quality Assurance in Medical Radiation Dosimetry, pp.193-208 (International Atomic Energy Agency, Vienna, Austria).

Chung E, Soisson E, Bouchard H, **Seuntjens JP** (2011) Advanced dosimetry techniques for accurate verification of nonstandard beams, Proceedings of IAEA International Symposium on Standards, Applications and Quality Assurance in Medical Radiation Dosimetry, International Atomic Energy Agency, Vienna, Austria pp.249-262.

Other

Op-ed piece, The Montreal Gazette (November 24, 2010), "Climate change is a real and present danger", **Mark Goldberg**, Peter Brown, Gail Chmura, Nicolas Kosoy, Thomas Naylor

- Featured in the Annual Report of the Research Institute of the MUHC, 2011.
- Featured in the Annual Report of the MUHC, 2011.

Reply on the Letter to the Editor on "Defining Radiotherapy Target Volumes Using (18)F-Fluoro-Deoxy-Glucose Positron Emission Tomography/Computed Tomography: Still a Pandora's Box?" (Devic et al. Int J Radiat Oncol Biol Phys 2010;78:1555-1562). Devic S, Faria S, **Lehnert S**. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):902-3.